For an elderly patient with dementia, how does brexpiprazole (Rexulti) compare to other antipsychotics regarding safety and efficacy?

Rexulti (Brexpiprazole) vs Other Antipsychotics for Elderly Patients with Dementia

Brexpiprazole should NOT be used in elderly patients with dementia-related psychosis without agitation, but it is FDA-approved specifically for agitation associated with Alzheimer's dementia at 2-3 mg/day and appears to have comparable or potentially lower mortality risk than other antipsychotics like aripiprazole. 1

Critical FDA Black Box Warning

The FDA label for Rexulti carries a black box warning: elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. Rexulti is NOT approved for treatment of patients with dementia-related psychosis without agitation associated with Alzheimer's disease. 1 This is the most important safety consideration that supersedes all other discussions.

When Brexpiprazole Can Be Used

Brexpiprazole is specifically FDA-approved for agitation associated with dementia due to Alzheimer's disease only—not for general dementia-related psychosis or behavioral symptoms. 1

Guideline Framework for Antipsychotic Use in Dementia

The 2016 APA guidelines emphasize that antipsychotic benefits in dementia are "at best small" and are consistently associated with clinically significant adverse effects including mortality. 2 Antipsychotics should only be considered for dangerous agitation or psychosis where the goal is to minimize violence risk, reduce patient distress, and decrease caregiver burden. 2

Treatment decisions must balance potential benefits against harms and involve the patient's surrogate decision maker, as the evidence shows modest efficacy at best. 2

Comparative Efficacy Data

Brexpiprazole Specific Evidence

Brexpiprazole 2 mg demonstrates optimal therapeutic benefit with the best risk-benefit profile. 3 The evidence shows:

• 2 mg dose: Significant CMAI score improvement versus placebo (mean difference -5.88 points, 95% CI: -8.13 to -3.63) and CGI-S improvement (MD: -0.48) 3
• 2-3 mg doses: Strongest NPI-NH improvements (MD: -4.60,95% CI: -7.54 to -1.66) 3
• Pooled analysis of 621 participants showed CMAI improvement of -4.50 points versus placebo (95% CI -6.90 to -2.10; Cohen's d 0.30) 4

Comparative Analysis Across Antipsychotics

A 2026 dose-response network meta-analysis comparing multiple antipsychotics found that aripiprazole 10 mg, brexpiprazole 1-2.5 mg, risperidone 1 mg, and olanzapine 2.5 mg were both effective and well-tolerated. 5 This positions brexpiprazole favorably among available options.

The analysis showed:

• Only aripiprazole 10 mg, brexpiprazole 1-2.5 mg, risperidone 1-2 mg, and olanzapine 2.5-5 mg were significantly more effective than placebo 5
• Tolerability remained acceptable for brexpiprazole up to 3 mg 5

Critical Safety Comparison: Mortality Risk

Real-world evidence from 41,871 Medicare beneficiaries with dementia showed 6-month mortality was statistically LOWER with brexpiprazole compared to aripiprazole (OR 0.49,95% CI 0.37-0.65). 6 This is particularly important given the black box warning applies to all antipsychotics in this population.

There was no statistical difference in emergency department visits or hospitalizations between brexpiprazole and aripiprazole. 6 However, when adjusted for unobserved confounding using two-stage least squares estimation, no statistically significant mortality differences were found, suggesting comparable safety profiles. 6

Safety and Tolerability Profile

Over 12 weeks in pooled trials (n=1,043):

• 51.1% on brexpiprazole vs 45.9% on placebo reported ≥1 treatment-emergent adverse event (TEAE) 7
• Discontinuation due to TEAEs: 6.3% brexpiprazole vs 3.4% placebo 7
• Headache was the only TEAE ≥5% incidence (7.6% brexpiprazole vs 9.3% placebo) 7
• Cerebrovascular events: 0.5% vs 0.3% 7
• Extrapyramidal symptoms: 5.3% vs 3.1% 7
• Somnolence/sedation: 3.7% vs 1.8% 7
• Deaths: 0.9% vs 0.3% (causes not considered related to brexpiprazole) 7

Minimal changes in weight, suicidality, extrapyramidal symptoms, and no worsening of cognition over 24 weeks. 7

Dosing Algorithm

Start brexpiprazole at 0.5 mg daily for Days 1-4, increase to 1 mg for Days 5-7, then 2 mg for Days 8-14. 1 The target maintenance dose is 2 mg daily, which provides optimal efficacy with favorable tolerability. 3

Dose may be increased to 3 mg if needed based on response, but higher doses (2-3 mg) show increased TEAEs (risk ratio 1.20-1.33) without proportional efficacy gains. 3

Dose adjustments required for:

• CYP2D6 poor metabolizers or strong CYP2D6 inhibitors: reduce dose by 50%
• Strong CYP3A4 inhibitors: reduce dose by 50%
• Combined strong CYP2D6 and CYP3A4 inhibitors: reduce to 25% of usual dose 8

Special Populations

Brexpiprazole improved agitation in patients with co-occurring psychosis (LSMD -9.18,95% CI -15.2 to -3.12; Cohen's d=0.52) and without psychosis (LSMD -4.22,95% CI -6.91 to -1.54; Cohen's d=0.29). 9 This suggests utility across the spectrum of Alzheimer's dementia presentations with agitation.

Concomitant antidepressant use: Brexpiprazole showed greater efficacy in participants taking antidepressants (LSMD -12.1, Cohen's d=0.72) versus those not taking antidepressants (LSMD -2.93, Cohen's d=0.20). 10 Falls were the only TEAE ≥5% in the antidepressant subgroup. 10

Clinical Decision Framework

1. Confirm diagnosis: Agitation associated with Alzheimer's dementia specifically (not other dementias or psychosis alone)
2. Exhaust non-pharmacological interventions first per guideline recommendations 2
3. Assess for dangerous agitation or severe distress that justifies antipsychotic use 2
4. Discuss black box mortality warning with surrogate decision makers 1
5. If proceeding, brexpiprazole 2 mg is the preferred dose based on optimal efficacy-tolerability balance 3
6. Monitor closely for cerebrovascular events, falls, extrapyramidal symptoms, and sedation 7
7. Brexpiprazole should be used as maintenance therapy, NOT as PRN 8

Important Caveats

• No head-to-head trials exist comparing brexpiprazole directly to risperidone, olanzapine, or quetiapine 8
• The clinical meaningfulness of a 4-5 point CMAI reduction remains debated 8
• Brexpiprazole has not been studied in non-Alzheimer's dementias (vascular, Lewy body, frontotemporal) 1
• The 2020 Canadian guidelines emphasize that all antipsychotic use in dementia should be time-limited and regularly reassessed for continued necessity 11